Switching from Mounjaro to Wegovy: what the evidence says

What did @ashlijohnson49 actually say?

She's been on Mounjaro (tirzepatide), it wrecked her stomach, she couldn't stop vomiting and had severe diarrhea, and it "killed her soul." Now she's spent £103 on Wegovy (semaglutide) and wants to know from real users whether switching medications actually reduces those side effects. Her specific theory: Mounjaro has "an extra hormone" that Wegovy doesn't, and she's hoping that's the reason for her bad reaction.

This is a reasonable, honest question from someone who had a genuinely rough experience. She's not claiming anything medical. She's crowdsourcing lived experience, which isn't ideal from an evidence standpoint, but it's also not misinformation. The "extra hormone" comment is the one thing worth examining more carefully, because she's almost right, but not quite in the way she thinks.

Does the science back this up?

The core observation, that tirzepatide produces more gastrointestinal side effects than semaglutide for some people, has real clinical support. The mechanism she gestures at is legitimate, even if her language is imprecise.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Semaglutide is a selective GLP-1 receptor agonist. The added GIP (glucose-dependent insulinotropic polypeptide) activity in tirzepatide is the "extra hormone" she's referring to. Whether that's responsible for worse GI tolerability is genuinely debated. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) reported nausea in roughly 30% of tirzepatide patients at the 15mg dose, with vomiting in about 15%. The STEP 1 trial for semaglutide 2.4mg (Wilding et al., 2021, NEJM) showed nausea in about 44% and vomiting in 24%, which is actually higher. So the "Wegovy is gentler" assumption isn't cleanly supported by head-to-head data. Both drugs have meaningful GI side effect profiles, and individual response varies considerably.

What did they get wrong (or right)?

She gets credit for correctly identifying that the two drugs work differently. Tirzepatide does have an additional mechanism that semaglutide lacks. That's accurate.

Where she slips is the implied conclusion: that the extra mechanism is why she had a worse experience, and that removing it will fix things. That's plausible but unproven for her specifically. GI side effects from GLP-1 drugs are largely driven by slowed gastric emptying, which is a shared mechanism in both medications (Heerspink et al., 2023, Diabetes Care). The GIP component in tirzepatide may actually reduce some GI burden in certain patients, not increase it. Her experience may reflect dose titration, individual gut sensitivity, or the specific formulation, not the dual-agonism per se. She also says she "badly needs a loss of beef" and admits she's "cheating" on diet, which is worth flagging: GLP-1 medications work better with dietary support, and using them as a pure shortcut without any lifestyle adjustment tends to produce worse tolerability outcomes.

What should you actually know?

If you've had severe GI side effects on one GLP-1 medication, switching to another may or may not help. The honest answer is: it depends on the person, the dose, and how the medication was titrated.

A few things are actually established. Slower dose titration significantly reduces nausea and vomiting on both semaglutide and tirzepatide (Davies et al., 2021, Lancet). Eating smaller, lower-fat meals while on these medications reduces gastric discomfort substantially. If someone genuinely cannot tolerate tirzepatide, switching to semaglutide is a clinically reasonable option, but it should be done under medical supervision, not based on TikTok comment sections. The £103 she spent on Wegovy should have come with a prescribing clinician who could walk her through exactly this question. If it didn't, that's a gap in her care, not a reason to crowdsource strangers online. Her distress is real and her question is fair. The answer just needs to come from someone reviewing her actual medical history.